{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:54Z","timestamp":1790913714474,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T00:00:00Z","timestamp":1491523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"ARIAD Pharmaceuticals, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia\u2010positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of this study was to compare overall survival (OS) between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogeneic stem cell transplantation (allo\u2010SCT).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>A post hoc, retrospective, indirect comparison of OS among patients who received single\u2010agent ponatinib in the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial with those who underwent allo\u2010SCT as reported to the European Bone Marrow Transplant registry, stratified by CML disease phase and Ph+ ALL, was conducted. Kaplan\u2010Meier survival curves and multivariate Cox proportional\u2010hazards models were used to compare OS between intervention groups, adjusting for time from diagnosis to intervention, age, sex, and geographic region; 24\u2010month and 48\u2010month OS rates and median OS were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>After adjustment for potential confounders, 24\u2010month and 48\u2010month OS rates were significantly higher in patients with chronic\u2010phase CML (CP\u2010CML) who received ponatinib compared with those who underwent allo\u2010SCT (24 months: 84% vs 60.5%, respectively; <jats:italic>P<\/jats:italic>\u2009=\u2009.004; 48 months: 72.7% vs 55.8%, respectively; <jats:italic>P<\/jats:italic>\u2009=\u2009.013), with a hazard ratio (HR) of 0.37 (95% confidence interval [CI], 0.16\u20100.84; <jats:italic>P<\/jats:italic>\u2009=\u2009.017). In patients who had accelerated\u2010phase CML, OS rates were not significantly different between the groups (HR, 0.90; 95% CI, 0.20\u20104.10; <jats:italic>P<\/jats:italic>\u2009=\u2009.889). In patients who had blast\u2010crisis CML and those with Ph+ ALL, ponatinib was associated with shorter OS compared with allo\u2010SCT (blast\u2010crisis CML: HR, 2.29 [95% CI, 1.08\u20104.82; <jats:italic>P<\/jats:italic>\u2009=\u2009.030]; Ph+ ALL: HR, 2.77 [95% CI, 0.73\u201010.56; <jats:italic>P<\/jats:italic>\u2009=\u2009.146]).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Although allo\u2010SCT remains an important treatment option for patients with T315I\u2010positive advanced CML and Ph+ ALL, ponatinib represents a valuable alternative for patients with T315I\u2010positive CP\u2010CML. <jats:bold><jats:italic>Cancer<\/jats:italic> 2017;123:2875\u201380.<\/jats:bold> \u00a9 <jats:italic>2017 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.30558","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T08:52:41Z","timestamp":1491555161000},"page":"2875-2880","source":"Crossref","is-referenced-by-count":93,"title":["Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome\u2010positive leukemias with the T315I mutation"],"prefix":"10.1002","volume":"123","author":[{"given":"Franck E.","family":"Nicolini","sequence":"first","affiliation":[{"name":"Hematology Department Lyon South\u2010Pierre\u2010B\u00e9nite Hospital Center and Unit 1052, National Institute of Health and Medical Research Lyon Cancer Research Center\/L\u00e9on Berard Center Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz W.","family":"Basak","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology and Internal Medicine, Medical University of Warsaw Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong\u2010Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"Leukemia Research Institute Seoul St. Mary's Hospital, The Catholic University of Korea Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Olavarria","sequence":"additional","affiliation":[{"name":"Department of Haematology Imperial College London, Hammersmith Hospital London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla\u2010Ibarz","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[{"name":"Department of Haematology Imperial College London, Hammersmith Hospital London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Pathology Royal Adelaide Hospital Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[{"name":"Department of Haematology and Medical Oncology, University of Leipzig Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Department of Leukemia Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Chuah","sequence":"additional","affiliation":[{"name":"Department of Haematology Singapore General Hospital, Duke\u2010NUS Medical School Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Clinic and Polyclinic for Internal Medicine II, Division of Hematology and Oncology Jena University Hospital Jena Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"L. e A. Seragnoli Institute of Hematology Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"DerSarkissian","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"McGarry","sequence":"additional","affiliation":[{"name":"ARIAD Pharmaceuticals, Inc Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.015974"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-242750"},{"key":"e_1_2_7_4_1","first-page":"243","article-title":"Resistant mutations in CML and Ph(+)ALL\u2014role of ponatinib","volume":"8","author":"Miller GD","year":"2014","journal-title":"Biologics."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29240"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.080234"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-219410"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-367326"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.10.004"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00012"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00207-7"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.281"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.30558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:46:54Z","timestamp":1760273214000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,7]]},"references-count":15,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1002\/cncr.30558"],"URL":"https:\/\/doi.org\/10.1002\/cncr.30558","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,7]]}}}